| Item Type | Name |
|
Concept
|
Oncogenes
|
|
Concept
|
Proto-Oncogene Proteins
|
|
Concept
|
Oncogene Proteins v-abl
|
|
Concept
|
Oncogene Proteins
|
|
Concept
|
Oncogene Proteins, Fusion
|
|
Concept
|
Proto-Oncogene Proteins c-fos
|
|
Concept
|
Proto-Oncogene Proteins c-abl
|
|
Concept
|
Proto-Oncogene Proteins c-crk
|
|
Concept
|
Proto-Oncogene Proteins c-vav
|
|
Concept
|
Oncogene Proteins, Viral
|
|
Concept
|
Proto-Oncogene Proteins c-pim-1
|
|
Concept
|
Proto-Oncogene Proteins c-bcl-2
|
|
Concept
|
Proto-Oncogene Proteins c-raf
|
|
Concept
|
Proto-Oncogene Proteins B-raf
|
|
Concept
|
Proto-Oncogene Proteins c-kit
|
|
Concept
|
Proto-Oncogene Proteins c-ret
|
|
Concept
|
Proto-Oncogene Proteins c-cbl
|
|
Concept
|
Proto-Oncogene Proteins p21(ras)
|
|
Concept
|
Proto-Oncogene Proteins c-met
|
|
Concept
|
Oncogene Protein v-cbl
|
|
Concept
|
Proto-Oncogene Proteins c-fyn
|
|
Concept
|
Proto-Oncogene Proteins c-akt
|
|
Academic Article
|
p210BCR/ABL induces formation of complexes containing focal adhesion proteins and the protooncogene product p120c-Cbl.
|
|
Academic Article
|
Steel factor induces tyrosine phosphorylation of CRKL and binding of CRKL to a complex containing c-kit, phosphatidylinositol 3-kinase, and p120(CBL).
|
|
Academic Article
|
Activation of hematopoietic growth factor signal transduction pathways by the human oncogene BCR/ABL.
|
|
Academic Article
|
p130CAS forms a signaling complex with the adapter protein CRKL in hematopoietic cells transformed by the BCR/ABL oncogene.
|
|
Academic Article
|
BCR/ABL induces multiple abnormalities of cytoskeletal function.
|
|
Academic Article
|
The phosphatidylinositol polyphosphate 5-phosphatase SHIP and the protein tyrosine phosphatase SHP-2 form a complex in hematopoietic cells which can be regulated by BCR/ABL and growth factors.
|
|
Academic Article
|
The proto-oncogene product p120CBL and the adaptor proteins CRKL and c-CRK link c-ABL, p190BCR/ABL and p210BCR/ABL to the phosphatidylinositol-3' kinase pathway.
|
|
Academic Article
|
The BCR/ABL oncogene alters interaction of the adapter proteins CRKL and CRK with cellular proteins.
|
|
Academic Article
|
Tyrosine phosphorylation of the product of the c-cbl protooncogene is [corrected] induced after integrin stimulation.
|
|
Academic Article
|
Hematopoietic growth factors signal through the formation of reactive oxygen species.
|
|
Academic Article
|
Role of focal adhesion proteins in signal transduction and oncogenesis.
|
|
Academic Article
|
Thrombopoietin induces activation of the phosphatidylinositol-3' kinase pathway and formation of a complex containing p85PI3K and the protooncoprotein p120CBL.
|
|
Academic Article
|
The bovine papillomavirus E6 protein binds to the LD motif repeats of paxillin and blocks its interaction with vinculin and the focal adhesion kinase.
|
|
Academic Article
|
Growth inhibition and modulation of kinase pathways of small cell lung cancer cell lines by the novel tyrosine kinase inhibitor STI 571.
|
|
Academic Article
|
The BCR/ABL oncogene alters the chemotactic response to stromal-derived factor-1alpha.
|
|
Academic Article
|
Molecular abnormalities in lung cancer.
|
|
Academic Article
|
Expression of the focal adhesion protein paxillin in lung cancer and its relation to cell motility.
|
|
Academic Article
|
Vascular endothelial growth factor-induced migration of multiple myeloma cells is associated with beta 1 integrin- and phosphatidylinositol 3-kinase-dependent PKC alpha activation.
|
|
Academic Article
|
Differential expression and signaling of CBL and CBL-B in BCR/ABL transformed cells.
|
|
Academic Article
|
SHIP1, an SH2 domain containing polyinositol-5-phosphatase, regulates migration through two critical tyrosine residues and forms a novel signaling complex with DOK1 and CRKL.
|
|
Academic Article
|
Regulation of cellular proliferation, cytoskeletal function, and signal transduction through CXCR4 and c-Kit in small cell lung cancer cells.
|
|
Academic Article
|
Role of the hepatocyte growth factor receptor, c-Met, in oncogenesis and potential for therapeutic inhibition.
|
|
Academic Article
|
Modulation of the c-Met/hepatocyte growth factor pathway in small cell lung cancer.
|
|
Academic Article
|
Role of receptor tyrosine kinases in lung cancer.
|
|
Academic Article
|
Activated c-Met signals through PI3K with dramatic effects on cytoskeletal functions in small cell lung cancer.
|
|
Academic Article
|
c-MET mutational analysis in small cell lung cancer: novel juxtamembrane domain mutations regulating cytoskeletal functions.
|
|
Academic Article
|
2-methoxyestradiol alters cell motility, migration, and adhesion.
|
|
Academic Article
|
Molecular alterations in lung cancer. Impact on prognosis.
|
|
Academic Article
|
Targeted molecules in small cell lung cancer.
|
|
Academic Article
|
Targeting c-Kit mutations: basic science to novel therapies.
|
|
Academic Article
|
Phase II study of imatinib in patients with small cell lung cancer.
|
|
Academic Article
|
Therapeutic targeting of the receptor tyrosine kinase Met.
|
|
Academic Article
|
A selective small molecule c-MET Inhibitor, PHA665752, cooperates with rapamycin.
|
|
Academic Article
|
Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer.
|
|
Academic Article
|
c-Met as a target for human cancer and characterization of inhibitors for therapeutic intervention.
|
|
Academic Article
|
Expression of Siva-1 protein or its putative amphipathic helical region enhances cisplatin-induced apoptosis in breast cancer cells: effect of elevated levels of BCL-2.
|
|
Academic Article
|
Activation of HGF/c-Met pathway contributes to the reactive oxygen species generation and motility of small cell lung cancer cells.
|
|
Academic Article
|
A selective small molecule inhibitor of c-Met, PHA665752, inhibits tumorigenicity and angiogenesis in mouse lung cancer xenografts.
|
|
Academic Article
|
c-Met inhibition.
|
|
Academic Article
|
c-Met: structure, functions and potential for therapeutic inhibition.
|
|
Academic Article
|
c-Met and hepatocyte growth factor: potential as novel targets in cancer therapy.
|
|
Academic Article
|
PAX5 is expressed in small-cell lung cancer and positively regulates c-Met transcription.
|
|
Academic Article
|
MET as a target for treatment of chest tumors.
|
|
Academic Article
|
The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma.
|
|
Academic Article
|
Expression and mutational analysis of MET in human solid cancers.
|
|
Academic Article
|
MET pathway as a therapeutic target.
|
|
Academic Article
|
Role of c-Met in cancer: emphasis on lung cancer.
|
|
Academic Article
|
Functional analysis of c-Met/hepatocyte growth factor pathway in malignant pleural mesothelioma.
|
|
Academic Article
|
PAX6 is expressed in pancreatic cancer and actively participates in cancer progression through activation of the MET tyrosine kinase receptor gene.
|
|
Academic Article
|
MET receptor tyrosine kinase.
|
|
Academic Article
|
Ethnic differences and functional analysis of MET mutations in lung cancer.
|
|
Academic Article
|
Fyn: a novel molecular target in cancer.
|
|
Academic Article
|
CBL is frequently altered in lung cancers: its relationship to mutations in MET and EGFR tyrosine kinases.
|
|
Academic Article
|
c-Met overexpression is a prognostic factor in ovarian cancer and an effective target for inhibition of peritoneal dissemination and invasion.
|
|
Academic Article
|
Rapid and dramatic radiographic and clinical response to an ALK inhibitor (crizotinib, PF02341066) in an ALK translocation-positive patient with non-small cell lung cancer.
|
|
Academic Article
|
Lysophosphatidic acid modulates c-Met redistribution and hepatocyte growth factor/c-Met signaling in human bronchial epithelial cells through PKC delta and E-cadherin.
|
|
Academic Article
|
Fyn is downstream of the HGF/MET signaling axis and affects cellular shape and tropism in PC3 cells.
|
|
Academic Article
|
Downstream signalling and specific inhibition of c-MET/HGF pathway in small cell lung cancer: implications for tumour invasion.
|
|
Academic Article
|
Non-receptor tyrosine kinase inhibitors in lung cancer.
|
|
Academic Article
|
FYN is overexpressed in human prostate cancer.
|
|
Academic Article
|
Effect of a c-Met-specific, ATP-competitive small-molecule inhibitor SU11274 on human ovarian carcinoma cell growth, motility, and invasion.
|
|
Academic Article
|
Inhibition of MET receptor tyrosine kinase and its ligand hepatocyte growth factor.
|
|
Academic Article
|
A novel classification of lung cancer into molecular subtypes.
|
|
Academic Article
|
Overexpression of the µ-opioid receptor in human non-small cell lung cancer promotes Akt and mTOR activation, tumor growth, and metastasis.
|
|
Academic Article
|
PAX3 and SOX10 activate MET receptor expression in melanoma.
|
|
Academic Article
|
Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer.
|
|
Academic Article
|
MET, HGF, EGFR, and PXN gene copy number in lung cancer using DNA extracts from FFPE archival samples and prognostic significance.
|
|
Academic Article
|
MET and phosphorylated MET as potential biomarkers in lung cancer.
|
|
Academic Article
|
Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.
|
|
Academic Article
|
Factor independence of human myeloid leukemia cell lines is associated with increased phosphorylation of the proto-oncogene Raf-1.
|
|
Academic Article
|
Inhibition of MET receptor tyrosine kinase and its ligand hepatocyte growth factor.
|
|
Academic Article
|
MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib.
|
|
Academic Article
|
Tyrosine kinase mutations in human cancer.
|
|
Academic Article
|
c-Met is a potentially new therapeutic target for treatment of human melanoma.
|
|
Academic Article
|
The thrombopoietin receptor c-MPL activates JAK2 and TYK2 tyrosine kinases.
|
|
Academic Article
|
Paxillin is a target for somatic mutations in lung cancer: implications for cell growth and invasion.
|
|
Academic Article
|
Review of clinic trials: agents targeting c-Met.
|
|
Academic Article
|
MET molecular mechanisms and therapies in lung cancer.
|
|
Academic Article
|
Novel oncogenic mutations of CBL in human acute myeloid leukemia that activate growth and survival pathways depend on increased metabolism.
|
|
Academic Article
|
NADPH oxidases regulate cell growth and migration in myeloid cells transformed by oncogenic tyrosine kinases.
|
|
Academic Article
|
Personalized treatment of lung cancer.
|
|
Academic Article
|
An E3 ubiquitin ligase: c-Cbl: a new therapeutic target of lung cancer.
|
|
Academic Article
|
Phase II study of the multitargeted tyrosine kinase inhibitor XL647 in patients with non-small-cell lung cancer.
|
|
Academic Article
|
Targeting ALK: a promising strategy for the treatment of non-small cell lung cancer, non-Hodgkin's lymphoma, and neuroblastoma.
|
|
Academic Article
|
Differential signaling after beta1 integrin ligation is mediated through binding of CRKL to p120(CBL) and p110(HEF1).
|
|
Academic Article
|
Involvement of the adapter protein CRKL in integrin-mediated adhesion.
|
|
Academic Article
|
Molecular and cellular biology of small cell lung cancer.
|
|
Academic Article
|
A novel small molecule met inhibitor induces apoptosis in cells transformed by the oncogenic TPR-MET tyrosine kinase.
|
|
Academic Article
|
Mechanisms of metastasis as related to receptor tyrosine kinases in small-cell lung cancer.
|
|
Academic Article
|
Key signaling pathways and targets in lung cancer therapy.
|
|
Academic Article
|
CD44 regulates hepatocyte growth factor-mediated vascular integrity. Role of c-Met, Tiam1/Rac1, dynamin 2, and cortactin.
|
|
Academic Article
|
C. elegans as a model organism for in vivo screening in cancer: effects of human c-Met in lung cancer affect C. elegans vulva phenotypes.
|
|
Academic Article
|
Disruption of the EGFR E884-R958 ion pair conserved in the human kinome differentially alters signaling and inhibitor sensitivity.
|
|
Academic Article
|
Expression patterns of PAX5, c-Met, and paxillin in neuroendocrine tumors of the lung.
|
|
Academic Article
|
Paxillin expression and amplification in early lung lesions of high-risk patients, lung adenocarcinoma and metastatic disease.
|
|
Academic Article
|
RON (MST1R) is a novel prognostic marker and therapeutic target for gastroesophageal adenocarcinoma.
|
|
Academic Article
|
Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification.
|
|
Academic Article
|
Role of MetMAb (OA-5D5) in c-MET active lung malignancies.
|
|
Academic Article
|
A phase I trial of pan-Bcl-2 antagonist obatoclax administered as a 3-h or a 24-h infusion in combination with carboplatin and etoposide in patients with extensive-stage small cell lung cancer.
|
|
Academic Article
|
Durable complete response of metastatic gastric cancer with anti-Met therapy followed by resistance at recurrence.
|
|
Academic Article
|
Increased tyrosine phosphorylation of focal adhesion proteins in myeloid cell lines expressing p210BCR/ABL.
|
|
Academic Article
|
Lack of association of C-Met-N375S sequence variant with lung cancer susceptibility and prognosis.
|
|
Academic Article
|
MET as a possible target for non-small-cell lung cancer.
|
|
Academic Article
|
Critical role of S1PR1 and integrin ß4 in HGF/c-Met-mediated increases in vascular integrity.
|
|
Academic Article
|
Initial clinical sensitivity and acquired resistance to MET inhibition in MET-mutated papillary renal cell carcinoma.
|
|
Academic Article
|
Lipopolysaccharide-induced phosphorylation of c-Met tyrosine residue 1003 regulates c-Met intracellular trafficking and lung epithelial barrier function.
|
|
Academic Article
|
Role of c-Met/phosphatidylinositol 3-kinase (PI3k)/Akt signaling in hepatocyte growth factor (HGF)-mediated lamellipodia formation, reactive oxygen species (ROS) generation, and motility of lung endothelial cells.
|
|
Academic Article
|
Activating the expression of human K-rasG12D stimulates oncogenic transformation in transgenic goat fetal fibroblast cells.
|
|
Academic Article
|
Analysis of 1,115 patients tested for MET amplification and therapy response in the MD Anderson Phase I Clinic.
|
|
Academic Article
|
MET and PI3K/mTOR as a potential combinatorial therapeutic target in malignant pleural mesothelioma.
|
|
Academic Article
|
Role of PAX8 in the regulation of MET and RON receptor tyrosine kinases in non-small cell lung cancer.
|
|
Academic Article
|
Crizotinib in ROS1-rearranged non-small-cell lung cancer.
|
|
Academic Article
|
Multiple Endocrine Disruption by the MET/ALK Inhibitor Crizotinib in Patients With Non-small Cell Lung Cancer.
|
|
Academic Article
|
Combined MET inhibition and topoisomerase I inhibition block cell growth of small cell lung cancer.
|
|
Academic Article
|
Dramatic antitumor effects of the dual MET/RON small-molecule inhibitor LY2801653 in non-small cell lung cancer.
|
|
Academic Article
|
AXL mediates resistance to cetuximab therapy.
|
|
Academic Article
|
Overcoming acquired resistance to cetuximab by dual targeting HER family receptors with antibody-based therapy.
|
|
Academic Article
|
c-Abl mediated tyrosine phosphorylation of paxillin regulates LPS-induced endothelial dysfunction and lung injury.
|
|
Academic Article
|
AXL Is a Logical Molecular Target in Head and Neck Squamous Cell Carcinoma.
|
|
Academic Article
|
A randomized phase II study of ganetespib, a heat shock protein 90 inhibitor, in combination with docetaxel in second-line therapy of advanced non-small cell lung cancer (GALAXY-1).
|
|
Academic Article
|
Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors.
|
|
Academic Article
|
MET as a drug target.
|
|
Academic Article
|
Phase II Study of the AKT Inhibitor MK-2206 plus Erlotinib in Patients with Advanced Non-Small Cell Lung Cancer Who Previously Progressed on Erlotinib.
|
|
Academic Article
|
ROS1 rearranged non-small cell lung cancer brain metastases respond to low dose radiotherapy.
|
|
Academic Article
|
C. elegans and mutants with chronic nicotine exposure as a novel model of cancer phenotype.
|
|
Academic Article
|
Selumetinib with and without erlotinib in KRAS mutant and KRAS wild-type advanced nonsmall-cell lung cancer.
|
|
Academic Article
|
Oncoprotein ZNF322A transcriptionally deregulates alpha-adducin, cyclin D1 and p53 to promote tumor growth and metastasis in lung cancer.
|
|
Academic Article
|
Effective growth-suppressive activity of maternal embryonic leucine-zipper kinase (MELK) inhibitor against small cell lung cancer.
|
|
Academic Article
|
Prognostic and Predictive Value in KRAS in Non-Small-Cell Lung Cancer: A Review.
|
|
Academic Article
|
Met gene amplification and protein hyperactivation is a mechanism of resistance to both first and third generation EGFR inhibitors in lung cancer treatment.
|
|
Academic Article
|
PI3 Kinase Pathway and MET Inhibition is Efficacious in Malignant Pleural Mesothelioma.
|
|
Academic Article
|
RETRACTED: The receptor tyrosine kinase AXL mediates nuclear translocation of the epidermal growth factor receptor.
|
|
Academic Article
|
Molecular profiling of metastatic colorectal tumors using next-generation sequencing: a single-institution experience.
|
|
Academic Article
|
Expression and mutational analysis of c-CBL and its relationship to the MET receptor in head and neck squamous cell carcinoma.
|
|
Academic Article
|
Oncoprotein ZNF322A transcriptionally deregulates alpha-adducin, cyclin D1 and p53 to promote tumor growth and metastasis in lung cancer.
|
|
Academic Article
|
MET in Lung Cancer: Biomarker Selection Based on Scientific Rationale.
|
|
Academic Article
|
Oncoprotein ZNF322A transcriptionally deregulates alpha-adducin, cyclin D1 and p53 to promote tumor growth and metastasis in lung cancer.
|
|
Academic Article
|
Differential responsiveness of MET inhibition in non-small-cell lung cancer with altered CBL.
|
|
Academic Article
|
The brigatinib experience: a new generation of therapy for ALK-positive non-small-cell lung cancer.
|
|
Academic Article
|
Focal adhesion kinase a potential therapeutic target for pancreatic cancer and malignant pleural mesothelioma.
|
|
Academic Article
|
B-Cell-Specific Diversion of Glucose Carbon Utilization Reveals a Unique Vulnerability in B Cell Malignancies.
|
|
Academic Article
|
Responses to Alectinib in ALK-rearranged Papillary Renal Cell Carcinoma.
|
|
Academic Article
|
Synergistic efficacy of RLIP inhibition and 2'-hydroxyflavanone against DMBA-induced mammary carcinogenesis in SENCAR mice.
|
|
Academic Article
|
Notch signaling in breast cancer: From pathway analysis to therapy.
|
|
Academic Article
|
Dose-escalation trial of the ALK, MET & ROS1 inhibitor, crizotinib, in patients with advanced cancer.
|
|
Academic Article
|
Precision medicine and actionable alterations in lung cancer: A single institution experience.
|
|
Academic Article
|
Radiomic prediction of mutation status based on MR imaging of lung cancer brain metastases.
|
|
Academic Article
|
Phase I Dose-Escalation and -Expansion Study of Telisotuzumab (ABT-700), an Anti-c-Met Antibody, in Patients with Advanced Solid Tumors.
|
|
Academic Article
|
The promise of selective MET inhibitors in non-small cell lung cancer with MET exon 14 skipping.
|
|
Academic Article
|
AXL Mediates Cetuximab and Radiation Resistance Through Tyrosine 821 and the c-ABL Kinase Pathway in Head and Neck Cancer.
|
|
Academic Article
|
MET receptor in oncology: From biomarker to therapeutic target.
|
|
Academic Article
|
Prolonged survival and response to tepotinib in a non-small-cell lung cancer patient with brain metastases harboring MET exon 14 mutation: a research report.
|
|
Academic Article
|
Prevention of mammary carcinogenesis in MMTV-neu mice by targeting RLIP.
|
|
Academic Article
|
The improbable targeted therapy: KRAS as an emerging target in non-small cell lung cancer (NSCLC).
|
|
Academic Article
|
Usefulness of Circulating Tumor DNA in Identifying Somatic Mutations and Tracking Tumor Evolution in Patients With Non-small Cell Lung Cancer.
|
|
Academic Article
|
Near-Complete Response to Combined Pembrolizumab and Platinum-Doublet in a Patient With STK11/KRAS Mutated Advanced Lung Adenocarcinoma.
|
|
Academic Article
|
AXL regulates neuregulin1 expression leading to cetuximab resistance in head and neck cancer.
|
|
Academic Article
|
Report of the First International Symposium on NUT Carcinoma.
|
|
Academic Article
|
Neighborhood disadvantage is associated with KRAS-mutated non-small cell lung cancer risk.
|
|
Academic Article
|
Precision oncology provides opportunities for targeting KRAS-inhibitor resistance.
|
|
Grant
|
ABNORMALITIES OF MOTILITY OF CML CELLS
|
|
Grant
|
Role of Paxillin in Lung Cancer
|
|
Grant
|
Novel Targeted Therapy in Pancreatic Cancer
|
|
Grant
|
PAXILLIN--AN ONCOGENE ACTIVATED PROTEIN
|
|
Academic Article
|
Dual Axl/MerTK inhibitor INCB081776 creates a proinflammatory tumor immune microenvironment and enhances anti-PDL1 efficacy in head and neck cancer.
|
|
Academic Article
|
Selpercatinib and Pralsetinib Induced Chylous Ascites in RET-Rearranged Lung Adenocarcinoma: A Case Series.
|
|
Academic Article
|
Acquired resistance to KRAS G12C small-molecule inhibitors via genetic/nongenetic mechanisms in lung cancer.
|
|
Academic Article
|
A Nexus between Genetic and Non-Genetic Mechanisms Guides KRAS Inhibitor Resistance in Lung Cancer.
|